医学分子生物学杂志2026，Vol.23Issue(3)：302-307,6.DOI:10.3870/j.issn.1672-8009.2026.03.009
1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤
1β-Hydroxyalantolactone Ameliorates Hepatic Injury in Rats with Nonalcoholic Steatohepatitis via AMPK/SREBP-1c Signaling Pathway
摘要
Abstract
Objective To investigate the effect of 1β-hydroxyalantolactone(1β-HA)on he-patic injury in rats with nonalcoholic steatohepatitis(NASH)through the AMPK/SREBP-1c signa-ling pathway.Methods A rat model of NASH was established by feeding with high-fat diet.The rats were administered 1β-HA at doses of 12.5,25.0,and 50.0 mg/kg by oral gavage for 4 weeks.Serum levels of HDL,TG,ALT,and AST were measured.Hepatic histopathology was as-sessed.The protein expression levels of α-SMA,MMP-1,TIMP-1,AMPK,and SREBP-1c were detected.The levels of IL-6,TNF-α,and IL-1β,as well as SOD activity and MDA concentration,were evaluated.Results Compared with the model group,the 1β-HA treatment groups showed sig-nificantly increased HDL levels and decreased TG,AST,and ALT levels(P<0.05);hepatic steatosis,inflammatory infiltration,and fibrosis were alleviated;the expression levels of α-SMA,TIMP-1,and SREBP-1c were down-regulated,while those of MMP-1 and AMPK were up-regulated(P<0.05);the levels ofIL-6,TNF-α,and IL-1β were reduced;SOD activity was elevated,and MDA concentration was decreased(P<0.05).Conclusion 1β-HA can ameliorate hepatic in-jury in NASH by activating AMPK and inhibiting the expression of SREBP-1c.关键词
1β-羟基土木香内酯/非酒精性脂肪性肝炎/脂肪变性/肝纤维化Key words
1β-hydroxyalantolactone/nonalcoholic steatohepatitis/steatosis/liver fibrosis分类
医药卫生引用本文复制引用
常健,张夏霞,田利英,袁芸菲,李森,宋枚芳,吴林霞..1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤[J].医学分子生物学杂志,2026,23(3):302-307,6.基金项目
河北省中医药管理局科研计划项目(No.2024194) This work was supported by a grant from the Research Program of Hebei Provincial Administration of Traditional Chinese Medicine(No.2024194) （No.2024194）
